早期癌症临床试验参与者经历的时间毒性
Sienna M Durbin1, Debra M Lundquist2, Andrea Pelletier3
1Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital & Harvard Medical School, Boston, MA.
JCO oncology practice
|June 10, 2024
概括
临床试验早期阶段 (EP-CTs) 的患者花费超过20%的时间在医疗保健访问上,这一指标被称为时间毒性. 在EP-CT中,较高的时间毒性与较差的癌症治疗结果有关.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 医疗保健服务研究 医疗服务研究
背景情况:
- 早期临床试验 (EP-CT) 对于开发新型癌症疗法至关重要.
- 在EP-CT期间患者与医疗保健系统的接触程度,称为"时间毒性",尚不清楚.
研究的目的:
- 在接受EP-CTs的患者中量化时间毒性.
- 为了确定增加时间毒性的预测因素.
- 评估癌症患者的时间毒性和临床结果之间的关联.
主要方法:
- 在EP-CT (2017-2019) 中对408名患者的电子健康记录进行了回顾性审查.
- 计算医疗保健相关日数作为试验日数总数的比例.
- 单变量和多变量分析以确定预测因素和回归模型以评估与结果的关联.
主要成果:
- 在EP-CTs期间,患者平均经历了22.5%的医疗保健相关日.
- 较高的时间毒性与特定的癌症类型 (胃肠道,头,乳腺) 相关,性能状况更差,以及向治疗.
- 高时间毒性与降低疾病应答率,无进展生存率和整体生存率相关.
结论:
- 在EP-CT中,患者将大量的试验时间用于医疗保健互动.
- 确定了时间毒性的预测因素,突出了患者和治疗特征.
- 高时间毒性是与EP-CTs上癌症患者的临床结果更差相关的重要因素,为患者咨询和试验设计提供了信息.
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Toxic Reactions: Overview
969
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
969
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
125
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
125
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K


